Patient‐reported outcomes from SYNERGY, a randomized, double‐blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Patient‐reported outcomes from SYNERGY, a randomized, double‐blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients

Published:2017-07-13 Issue:1 Volume:37 Page:394-406
ISSN:0733-2467
Container-title:Neurourology and Urodynamics
language:en
Short-container-title:Neurourology and Urodynamics

Author:

Robinson Dudley¹,Kelleher Con²,Staskin David³,Mueller Elizabeth R.⁴,Falconer Christian⁵,Wang Jianye⁶,Ridder Arwin⁷,Stoelzel Matthias⁷,Paireddy Asha⁷,van Maanen Rob⁷,Hakimi Zalmai⁸,Herschorn Sender⁹

Affiliation:

1. King's College HospitalLondonUK

2. Guy's and St Thomas’ HospitalLondonUK

3. Tufts University School of MedicineBostonMassachusetts

4. Loyola University ChicagoStritch School of MedicineMaywoodIllinois

5. Karolinska InstituteStockholmSweden

6. Beijing HospitalBeijingChina

7. Astellas Pharma Global DevelopmentLeidenNetherlands

8. Astellas Pharma Europe LtdSurreyUK

9. Sunnybrook Health Sciences CentreTorontoOntarioCanada

Funder

Astellas Pharma Europe

Publisher

Wiley

Subject

Urology,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/nau.23315

Reference25 articles.

1. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study

2. Economic burden of urgency urinary incontinence in the United States: a systematic review;Coyne KS;J Manag Care Pharm,2014

3. Global Prevalence and Economic Burden of Urgency Urinary Incontinence: A Systematic Review

4. Prevalence and burden of overactive bladder in the United States;Stewart WF;World J Urol,2003

5. Patient-reported outcomes in overactive bladder: Importance for determining clinical effectiveness of treatment

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials;Frontiers in Surgery;2024-08-26

2. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder;Neurourology and Urodynamics;2024-07-15

3. The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder;Journal of Urology;2024-07

4. Cost-Utility Analysis of Mirabegron Compared to Solifenacin in the Treatment of Overactive Bladder (OAB) in Iran;Iranian Journal of Pharmaceutical Research;2023-11-08

5. Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms—A randomized controlled trial;LUTS: Lower Urinary Tract Symptoms;2023-05-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3